Pyxis Oncology (PYXS) said Tuesday it will present new preclinical data from its phase 1 study of micvotabart pelidotin, antibody-drug conjugate to treat recurrent and metastatic head and neck squamous cell carcinoma, at the American Association for Cancer Research Meeting in Chicago in April.
In phase 1 trial, the drug showed monotherapy effect on multiple tumor types with significant tumor regression, according to the company. It has begun the part 2 monotherapy expansion cohorts of the ongoing Phase 1 to assess Micvo in second-line and third-line recurrent and metastatic head and neck squamous cell carcinoma patients who have received prior platinum and PD-1 inhibitor therapy and those who received prior EGFRi and PD-1 inhibitor therapy.
The company added that preliminary data for patients who received prior platinum and PD-1 inhibitor therapy are expected in H2. Preliminary data from those who received prior EGFRi and PD-1 inhibitor therapy are expected in H1 2026.
The company said it also started a phase 1/2 combination study of Micvo and Merck's anti-PD-1 therapy, Keytruda, in patients with R/M HNSCC and other solid tumors to identify the recommended Phase 2 dose by mid-2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.